Sun Yat-sen University: Colorectal Neoplasms trials

The registry lists 91 Colorectal Neoplasms studies with Sun Yat-sen University as lead sponsor. 45 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 51Phase 3 21No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer PatientsRecruitingNCT07809893Phase 2
• Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRDRecruitingNCT07775950Not applicable
• FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
• Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal CancerNot yet recruitingNCT07714447Phase 2
• FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingNCT07621497Phase 2
• Construction and Evaluation of a Flipped Discharge Model for Stomates With Colorectal CancerNot yet recruitingNCT07463690Not applicable
• Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingNCT07448142Phase 2
• Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerNot yet recruitingNCT07405736Phase 2
• Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingNCT07261709Phase 2
• A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal CancerNot yet recruitingNCT07254156
• Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal CancerNot yet recruitingNCT07059338Phase 2
• AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal CancerNot yet recruitingNCT07021950Phase 2
• A Multi-omics Study of BRAF V600E Mutant Colorectal CancerNot yet recruitingNCT07007689
• A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT06959693Phase 2/3
• Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerRecruitingNCT06903858Phase 2
• DYNAMICS-LYNCH：DNA Methylation Analysis in Stool for Screening of Lynch Syndrome-Associated Colorectal CancerNot yet recruitingNCT06772844
• ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study ProtocolNot yet recruitingNCT06710860Not applicable
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer StudyRecruitingNCT06547203Phase 2
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerRecruitingNCT06520683Phase 3
• Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal CancerRecruitingNCT06441565Phase 2/3
• Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal CancerNot yet recruitingNCT06434090Phase 1/2
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC PatientsRecruitingNCT06280495Phase 2/3
• Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before SurgeryRecruitingNCT06262581Phase 2
• Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLMRecruitingNCT06208371Phase 3
• Crisaborole Ointment for Skin Toxicity Induced by CetuximabRecruitingNCT06118047Phase 2
• Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation TherapyNot yet recruitingNCT06099951Phase 2
• Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyRecruitingNCT06018714Phase 2
• Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal CancerRecruitingNCT06014372Phase 2
• Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapyRecruitingNCT05962502Phase 2
• Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingNCT05959356Phase 2
• Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal CancerRecruitingNCT05933980Phase 2
• Construction and Validation of Risk Prediction Model for Gastrointestinal Dysfunction of Patient With Colorectal CancerRecruitingNCT05891301
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver MetastasesRecruitingNCT05794971Phase 3
• Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRCRecruitingNCT05768503Phase 3
• A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.RecruitingNCT05731336
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM PatientsRecruitingNCT05727163Phase 2
• RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal CancerRecruitingNCT05578287Phase 2
• Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal CancerRecruitingNCT05571644Phase 2
• Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for SurveillanceRecruitingNCT05528783
• Preoperative Systemic Therapy for Colorectal Cancer Peritoneal MetastasesNot yet recruitingNCT05353582Phase 2
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal CancerRecruitingNCT05236972Phase 3
• mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal CancerRecruitingNCT04338191Phase 3
• Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerRecruitingNCT03926338Phase 2
• PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal CancerRecruitingNCT03638297Phase 2
• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRCRecruitingNCT03303495Phase 3
• Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC PatientsCompletedNCT07320950Phase 3
• Impact of Body Mass Index and Lipid Metabolism on Anti-PD-1 Immunotherapy Outcomes in Colorectal CancerCompletedNCT07012174
• Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant ImmunotherapyCompletedNCT06980350
• Surgery Following Immune Checkpoint Inhibitions for Controlled Disease in Recurrent or Metastatic dMMR/MSI-H Colorectal CancerCompletedNCT06717763
• Dyadic Intervention for Psychological Distress of Patients With Colorectal Cancer and Their SpousesCompletedNCT06326437Not applicable
• Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer RecurrenceActive, not recruitingNCT06143644
• Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal CancerCompletedNCT05775900Phase 1/2
• Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal CancerWithdrawnNCT05690035Phase 2
• Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLMStatus unknownNCT05485909Phase 2
• Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerActive, not recruitingNCT05426005Phase 1/2
• Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCStatus unknownNCT05004831Phase 2
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
• PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal CancerActive, not recruitingNCT04833387Phase 2
• Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal CancerCompletedNCT04790448Phase 1/2
• Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingNCT04724239Phase 2
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
• The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and SurvivalCompletedNCT04482608
• The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibodyCompletedNCT04466267
• Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal CancerActive, not recruitingNCT04304209Phase 2
• PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal CancerActive, not recruitingNCT04301557Phase 2
• Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal CancerActive, not recruitingNCT04262635Phase 3
• The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal CancerStatus unknownNCT04230018
• Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRCStatus unknownNCT04228614
• Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal CancerStatus unknownNCT04030260Phase 2
• JS001 Combined With Regorafenib in Patients With Advanced Colorectal CancerStatus unknownNCT03946917Phase 1/2
• Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal CancerStatus unknownNCT03912857Phase 2
• A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal CancerStatus unknownNCT03904537Phase 1/2
• FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLMTerminatedNCT03678428Phase 3
• Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLMTerminatedNCT03500874Phase 3
• Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLMActive, not recruitingNCT03493048Phase 2
• Systemic Screening for Hereditary Colorectal Cancer in ChinaStatus unknownNCT03365986
• ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal CancerStatus unknownNCT03312374
• Vitamin C Intravenously With Chemotherapy in Advanced Colorectal CancerCompletedNCT02969681Phase 3
• Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal CancerCompletedNCT02909478Phase 3
• Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B CarriersStatus unknownNCT02777814Phase 2
• FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeCompletedNCT02350530Phase 2
• Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer PatientsStatus unknownNCT02149784Phase 3
• FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal CancerStatus unknownNCT02128425Phase 2
• FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal CancerCompletedNCT02063529Phase 2
• Maintenance Treatment With Capecitabine in Colorectal Cancer PatientsStatus unknownNCT02027363Phase 2
• Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal CancerStatus unknownNCT01912443
• Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal CancerStatus unknownNCT01880658Phase 2
• Identification the Expression of Sox2 in Colorectal Cancer TissuesCompletedNCT01589900
• FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal CancerStatus unknownNCT01566942Phase 3
• Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and SafetyStatus unknownNCT01465451Phase 3
• Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI TumorStatus unknownNCT01048463Phase 3